Raphael Pharmaceutical (RAPH) EBITDA (2020 - 2024)

Raphael Pharmaceutical has disclosed EBITDA across 5 years of filings, most recently posting -$394000.0 for Q4 2024.

• EBITDA for Q4 2024 came in at -$394000.0, down 394.03% year-over-year; the trailing twelve-month figure through Dec 2024 was -$1.5 million (down 18.63% YoY), and the FY2025 annual result was -$1.2 million, up 17.5% from the prior year.
• EBITDA came in at -$394000.0 for Q4 2024 at Raphael Pharmaceutical, down from -$319000.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $134000.0 in Q4 2023 to a low of -$1.4 million in Q3 2022.
• The 5-year median for EBITDA is -$389500.0 (2021), against an average of -$454944.4.
• Across the five-year window, EBITDA jumped 112.14% in 2023 and sank 394.03% in 2024, its largest moves.
• Raphael Pharmaceutical's EBITDA stood at -$227000.0 in 2020, then tumbled by 152.86% to -$574000.0 in 2021, then slumped by 92.33% to -$1.1 million in 2022, then jumped by 112.14% to $134000.0 in 2023, then tumbled by 394.03% to -$394000.0 in 2024.
• The last three EBITDA figures came in at -$394000.0 (Q4 2024), -$319000.0 (Q3 2024), and -$249000.0 (Q2 2024), per Business Quant data.